Skip to main content

Table 2 Abnormal levels of biomarkers related to coagulation disorders in our study cohort (N: 235)

From: Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting

Variable N Mean (SD) Patients with abnormal levels of biomarkers N (%)a
DD 232 215.13 (174.47) 63 (27.0)
TAT 235 4.94 (3.23) 34 (40.0)
F 1 + 2 235 207.76 (81.18) 97 (41.3)
PAI-1 235 32.46 (23.61) 113 (48.1)
FVIII 235 131.28 (33.65) 29 (12.3)
  1. PAI-1 plasminogen activator inhibitor type 1, F1 + 2 fragment 1 + 2, TAT thrombin antithrombin complex, FVIII factor VIII, DD d-dimer
  2. aCut-off values for case discrimination were defined upon the mean + 2SD of each biomarker as assessed in the control group (N: 150)